Finnish Biotech Secures U.S. Patent for Ivermectin-based Nasal Spray to Take on COVID-19 in Low-to-Middle-Income Countries (LMICs)

A biotech venture based in Turku, Finland, called Therapeutica Borealis just secured a patent from the United States Patent and Trademark Office (USPTO) for its COVID-19 therapy based on ivermectin and a few other notable therapies: hydroxychloroquine and aprotinin. Developed as a nasal spray, which can challenge the virus’ ability to enter the body and replicate, this particular investigational product can be mass-produced at low cost and distributed to parts around the world where vaccination may be less pervasive. Now the company seeks pharmaceutical company partners to scale up research and go-to-market.


